VIRAL HEMORRHAGIC FEVERS IN THE ASIAN PART OF ASIAN-PACIFIC REGION: EPIDEMIOLOGY, POTENTIALS FOR SPECIFIC TREATMENT, AND PREVENTION
https://doi.org/10.17238/PmJ1609-1175.2019.3.11-18
Abstract
Literature review covers viral hemorrhagic fevers (VHF) in countries of Asian part of Asia-Pacific Region. We presented regional extensiveness and tendencies of incidence of most prevailing VHF such as Dengue fever, hemorrhagic fever with renal syndrome, and severe fever with thrombocytopenia syndrome, and also possibilities to prevent them. We approach a problem of specific treatment of VHF considering mechanisms of action and cytotoxicity of drugs, and tendencies of usage of less toxic pluripotential recovered from hydrobionts of Pacific Ocean as well.
About the Authors
G. G. Kompanets
Somov Institute of Epidemiology and Microbiology
Far-Eastern Federal University
Russian Federation
Russian Federation
1 Selskaya St. Vladivostok 690087 Russian Federation
10 Ajax Bay of Russky Island, Vladivostok 690922 Russian Federation
O. V. Iunikhina
Somov Institute of Epidemiology and Microbiology
Pacific State Medical University
Russian Federation
Russian Federation
1 Selskaya St. Vladivostok 690087 Russian Federation
2 Ostryakova Ave. Vladivostok 690002 Russian Federation
A. B. Pott
Somov Institute of Epidemiology and Microbiology
Russian Federation
1 Selskaya St. Vladivostok 690087 Russian Federation
Russian Federation
1 Selskaya St. Vladivostok 690087 Russian Federation
N. V. Krylova
Somov Institute of Epidemiology and Microbiology
Russian Federation
1 Selskaya St. Vladivostok 690087 Russian Federation
Russian Federation
1 Selskaya St. Vladivostok 690087 Russian Federation
References
1. Zhan J., Wang Q., Cheng J. [et al.]. Current status of severe fever with thrombocytopenia syndrome in China // Virologica Sinica. 2017. Vol. 32, No. 1. P. 51–62.
2. Berlizova M.V., Lubova V.A., Kurlovskaya A.V., Leonova G.N. Ixodicticks as carriers of natural focal disease pathogens in the epidemic season of 2017 in the territory of Primorsky Krai // Health. Medical Ecology. Science. 2018. Vol. 1, No. 73. P. 4–12.
3. Besednova N.N., Makarenkova I.D., Zvyagintseva T.N. [et al.]. Antiviral effect and pathogenetic targets of sulfated algae polysaccharides in herpes virus infections // Biomedical chemistry. 2016. Vol. 62, No. 3. P. 217–227.
4. Burganova A.N. Comparative evaluation of certain types of etiotropic therapy of HFRS: Author’s abstract … cand. med. sci. Ufa, 2001. 22 p.
5. Zaporozhets T.S., Gaja A.K., Zvyagintseva T.N. [et al.]. Cellular and molecular mechanisms of the immunomodulating action of fucoidan from the brown alga Fucus evanescens // Pacific Medical Journal. 2018. No. 4. P. 49–52.
6. Kompanets G.G., Maksema I.G., Iunihina O.V. [et al.]. Features of mixed foci of hantavirus infection in Vladivostok municipal district // Pacific Medical Journal. 2010. No. 3. P. 40–43.
7. Lvov D.K., Alhovskij S.V., Shhelkanov M.Ju. [et al.]. Genetic characterization of Powassan virus isolated from Haemaphysalis longicornis ticks in the Primorsky Krai and two strains of the tick-borne encephalitis virus: Alma-Arasan virus isolated from the Ixodes persulcatus ticks in Kazakhstan and Malyshevo virus isolated from the Aedes vexans nipponii mosquitoes in the Khabarovsk Territory // Voprosy Virusologii. 2014. Vol. 59, No. 5. P. 18–22.
8. Makarenkova I.D., Kompanets G.G., Besednova N.N. [et al.]. Screening of biopolymers from marine hydrobionts affecting the adsorption of the Hantaan virus // Voprosy Virusologii. 2007. No. 2. P. 29–32.
9. Makarenkova I.D., Besednova N.N., Zaporozhets T.S., Antiviral effect of sulfated polysaccharides // Antibiotics and Chemotherapy. 2009. Vol. 54, No. 1–2. P. 56–62.
10. Maksema I.G., Makarenkova I.D. Antiviral activity of natural origin fucoidans in experimental infection caused by hantavirus // Pacific Medical Journal. 2008. No. 2. P. 86–88.
11. Maksema I.G., Kompanets G.G., Barabanova A.O. [et al.]. Antiviral effect of carrageenans from red algae during experimental hantavirus infection // Pacific Medical Journal. 2012. No. 1. P. 32–34.
12. Mingazova E.M., Shaikhullina L.R., Valishin D.A., Hunafina D.Kh. Modern aspects of etiotropic treatment of hemorrhagic fever with renal syndrome // Medical Bulletin of Bashkortostan. 2015. Vol. 10, No. 1. P. 108–112.
13. Morozov V.G. The use of the inducer of endogenous interferon amixin for the treatment of hemorrhagic fever with renal syndrome // Russian Medical Journal. 2001. No. 15. P. 656–657.
14. Obraztsov Yu.G., Slonova R.A., Kompanets G.G. [et al.]. Effectiveness of antiviral therapy for hemorrhagic fever with renal syndrome (HFRS) // Far Eastern Journal of Infectious Pathology. 2005. No. 6. P. 58–59.
15. Slonova R.A., Kushnareva T.V., Kompanets G.G. [et al.]. Hantavirus infections in Primorsky Krai – epidemiological situation in the foci of different virus serotypes circulation // Journal of Microbiology, Epidemiology and Immunobiology. 2006. No. S3. P. 74–77.
16. Tkachenko E.A., Bernstein A.D., Dzagurova T.K. [et al.]. Actual problems of hemorrhagic fever with renal syndrome // Journal of Microbiology, Epidemiology and Immunobiology. 2013. No. 1. P. 51–58.
17. Tkachenko E.A., Ishmuhametov A.A., Dzagurova T.K. [et al.]. Development of an experimental industrial vaccine production technology for the prevention of hemorrhagic fever with renal syndrome // Remedium. 2015. No. 6. P. 47–54.
18. Yudintseva E.V. Clinical and immunological characteristics and immunoactive therapy of patients with hemorrhagic fever with renal syndrome: Author’s abstract … cand. med. sci. Saint Petersburg, 2009. 21 p.
19. Aman M.J., Kinch M.S., Warfield K. [et al.]. Development of a broad-spectrum antiviral with activity against Ebola virus // Antivir. Res. 2009. Vol. 83, No. 3. P. 245–251.
20. Arai S., Kikuchi F., Bawm S. [et al.]. Molecular phylogeny of Mobatviruses (Hantaviridae) in Myanmar and Vietnam // Viruses. 2019. Vol. 11, No. 3. P. 1–15.
21. Banu S., Hu W., Hurst C., Tong S. Dengue transmission in the Asia-Pacific region: impact of climate change and socioenvironmental factors // Trop. Med. Int. Health. 2011. Vol. 16, No. 5. P. 598–607.
22. Banu S., Hu W., Guo Y. [et al.]. Dynamic spatiotemporal trends of Dengue transmission in the Asia-Pacific Region, 1955–2004 // PLoS ONE. 2014. Vol. 9, No. 2. P. 1–7.
23. Beard C. B., Occi J., Bonilla D.L., [et al.]. Multistate infestation with the exotic disease – vector tick haemaphysalis longicornis – United States, August 2017 – September 2018 // Morb. Mortal. Wkly. Rep. 2018. Vol. 67, No. 47. P. 1310–1313.
24. Bhatt S., Gething P.W., Brady O.J. [et al.]. The global distribution and burden of dengue // Nature. 2013. Vol. 496. P. 504–507.
25. Bossi P., Tegnell A., Baka A. [et al.]. Task force on biological and chemical agent threats, Public Health Directorate, European Commission, Luxembourg. Bichat guidelines for the clinical management of haemorrhagic fever viruses and bioterrorism-related haemorrhagic fever viruses // Eurosurveillance. 2004. Vol. 9. P. 11–12.
26. Bray M. Pathogenesis of viral hemorrhagic fever // Curr. Opin. Immunol. 2005. Vol. 17, No. 4. P. 399–403.
27. Burk R., Bollinger L., Johnson J. C. [et al.]. Neglected filoviruses // FEMS Microbiol. Rev. 2016. Vol. 40, No. 4. P. 494–519.
28. Cantoni D., Hamlet A., Michaelis M. [et al.]. Risks posed by Reston, the forgotten Ebolavirus // mSphere. 2016. Vol. 1, No. 6. P. 1–10.
29. Cao Y.G., Hao Y., Li Z.H. [et al.]. Antiviral activity of polysaccharide extract from Laminaria japonica against respiratory syncytial virus // Biomedicine & Pharmacotherapy. 2016. Vol. 84. P. 1705–1710.
30. Chen J., Lu H. Yellow fever in China is still an imported disease // BioScience Trend. 2016. Vol. 10, No. 2. P. 158–162.
31. Cobo F. Viruses causing hemorrhagic fever. Safety laboratory procedures // Open Virol. J. 2016. No. 10. P. 1–9.
32. Decheng B., Yu B., Han Q. [et al.]. Immune activation of RAW264.7 macrophages by low molecular weight fucoidan extracted from New Zealand Undaria pinnatifida // J. Agric. Food Chem. 2018. Vol. 66, No. 41. P. 10721–10728.
33. Dubot-Pérès A., Vongphrachanh P., Denny J. [et al.]. An epidemic of dengue-1 in a remote village in rural Laos // PLoS Negl. Trop. Dis. 2013. Vol. 7, No. 8. P. 1–11.
34. Ergonul O. Treatment of Crimean-Congo hemorrhagic fever // Antivir. Res. 2008. Vol. 78, No. 1. P. 125–131.
35. Fang L.Q., Liu K., Li X.L. [et al.]. Emerging tick-borne infections in mainland China: An increasing public health threat // Lancet Infect. Dis. 2015. Vol. 15, No. 12. P. 1467–1479.
36. Furuta Y., Komeno T., Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase // Proc. Jpn Acad., Ser. B, Psychical and Biological Sciences. 2017. Vol. 93, No. 7. P. 449–463.
37. Geisbert T.W., Jahrling P.B. Exotic emerging viral diseases: progress and challenges // Nature Medicine. 2004. Vol. 10. P. 110–121.
38. He X., Wang S., Huang X., Wang X. Changes in age distribution of hemorrhagic fever with renal syndrome: An implication of China›s expanded program of immunization // BMC Public Health. 2013. Vol. 13, No. 394. P. 1–6.
39. Hidari K.I., Takahashi N., Arihara M. [et al.]. Structure and antidengue virus activity of sulfated polysaccharide from a marine alga // Biochem. Biophys. Res. Commun. 2008. Vol. 376, No. 1. P. 91–95.
40. Hirabayashi Y., Oka S., Goto H. [et al.]. The first imported case of Lassa fever in Japan (in Japanese) // Nippon rinsho. Jap. J. Clin. Med. 1989. No. 47. P. 71–75.
41. Holmes E.C., Tio P.H., Perera D. [et al.]. Importation and cocirculation of multiple serotypes of dengue virus in Sarawak, Malaysia // Virus Research. 2009. Vol. 143, No. 1. P 1–5.
42. Ippolito G., Feldmann H., Lanini S. [et al.]. Viral hemorrhagic fevers: Advancing the level of treatment // BMC Med. 2012. Vol. 10, No. 31. P. 1–8.
43. Jarman R. G., Holmes E. C., Rodpradit P. [et al.]. Microevolution of Dengue viruses circulating among primary school children in Kamphaeng Phet, Thailand // J. Virol. 2008. Vol. 82. P. 5494–5500.
44. Jonsson C.B., Figueiredo L.T.M., Vapalahti O.A. Global Perspective on Hantavirus Ecology, Epidemiology, and Disease // Clin. Microbiol. Rev. 2010. Vol. 23, No. 2. P. 412–441.
45. Kim Y.I., Oh W.S., Song P.H. [et al.]. Anti-photoaging effects of low molecular-weight Fucoidan on ultraviolet B-irradiated mice // Marine Drugs. 2018. Vol. 16, No. 8. P. 286.
46. Kim K.H., Lee M.J., Ko M.K. [et al.]. Severe fever with thrombocytopenia syndrome patients with hemophagocytic lymphohistiocytosis retrospectively identified in Korea, 2008–2013 // J. Korean Med. Sci. 2018. Vol. 33, No. 50. P. 1–5.
47. Koksal I., Yilmaz G., Aksoy F. [et al.]. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections // Antivir. Res. 2009. Vol. 82, No. 3. P. 95–102.
48. Koksal I., Yilmaz G., Aksoy F. [et al.]. The efficacy of ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Eastern Black Sea region in Turkey // J. Clin. Virol. 2010. Vol. 47, No. 1. P. 65–68.
49. Liu K., Zhou H., Sun R.X. [et al.]. A national assessment of the epidemiology of severe fever with thrombocytopenia syndrome. China // Scientific Reports. 2015. No. 5. P. 1–8.
50. Maes P., Adkins S., Alkhovsky S.V. [et al.]. Taxonomy of the order Bunyavirales: Second update // Arch. Virol. 2018. Vol. 163, No. 8. P. 2295–2310.
51. Malinin O.V., Platonov A.E. Insufficient efficacy and safety of intravenous ribavirin in treatment of haemorrhagic fever with renal syndrome caused by Puumala virus // Infect. Dis. 2017. Vol. 49, No. 7. P. 514–520.
52. Milholland M.T., Castro-Arellano I., Suzán G. [et al.]. Global diversity and distribution of hantaviruses and their hosts // EcoHealth. 2018. Vol. 15. P 1–46.
53. Miranda M.E., Ksiazek T.G., Retuya T.J. [et al.]. Epidemiology of Ebola (subtype Reston) virus in the Philippines // J. Infect. Dis. 1999. Vol. 179 (Suppl. 1). P. 115–119.
54. Moreli M.L., Marques-Silva A. C., Pimentel V.A., da Costa V. Effectiveness of the ribavirin in treatment of hantavirus infections in the Americas and Eurasia: A meta-analysis // Vir. Dis. 2014. Vol. 25, No. 3. P. 385–389.
55. Ngwe Tun M.M., Kyaw A.K., Makki N. [et al.]. Characterization of the 2013 dengue epidemic in Myanmar with dengue virus 1 as the dominant serotype // Infection, Genetics and Evolution. 2016. Vol. 43. P. 31–37.
56. Onoa L., Wollinger W., Rocco I.M. [et al.]. In vitro and in vivo antiviral properties of sulfated galactomannans against yellow fever virus (BeH111 strain) and dengue 1 virus (Hawaii strain) // Antivir. Res. 2003. Vol. 60, No. 3. P. 201–208.
57. Park Y. Epidemiologic study on changes in occurrence of hemorrhagic fever with renal syndrome in Republic of Korea for 17 years according to age group: 2001–2017 // BMC Infect. Dis. 2019. Vol. 19, No. 153. P. 1–8.
58. Paragas J., Whitehouse C.A., Endy T.P., Bray M. A simple assay for determining antiviral activity against Crimean-Congo hemorrhagic fever virus // Antivir. Res. 2004. Vol. 62, No. 1. P. 21–25.
59. Robles N.J.C., Han H.J., Park S.J., Choi Y.K. Epidemiology of severe fever and thrombocytopenia syndrome virus infection and the need for therapeutics for the prevention // Clin. Exp. Vaccine Res. 2018. Vol. 7, No. 1. P. 43–50.
60. Rusnak J.M., Byrne W.R., Chung K.N. [et al.]. Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea // Antivir. Res. 2009. Vol. 81, No. 1. P. 68–76.
61. Saito T., Fukushima K., Umeki K., Nakajima K. Severe fever with thrombocytopenia syndrome in Japan and public health communication // Emerg. Infect. Dis. 2015. Vol. 21, No. 3. P. 487–489.
62. Sharifi-Mood B., Metanat M., Ghorbani-Vaghei A. [et al.]. The outcome of patients with Crimean-Congo hemorrhagic fever in Zahedan, southeast of Iran: a comparative study // Arch. Iran. Med. 2009. Vol. 12, No. 2. P. 151–153.
63. Silvas J.A., Aguilar P.V. The emergence of severe fever with thrombocytopenia syndrome virus // Am. J. Trop. Med. Hyg. 2017. Vol. 97, No. 4. P. 992–996.
64. Simmons C.P., Farrar J.J., Chau N.V., Wills B. Dengue // N. Engl. J. Med. 2012. Vol. 366, No. 15. P. 1423–1432.
65. Sun T.H., Zhang X.H., Miao Y. [et al.]. Studies on antiviral and immuno-regulation activity of low molecular weight fucoidan from Laminaria japonica // Journal of Ocean University of China. 2018. Vol. 317. P. 705–711.
66. Tajima S., Nakayama E., Kotaki A. [et al.]. Whole genome sequencing-based molecular epidemiologic analysis of autochthonous dengue virus type 1 strains circulating in Japan in 2014 // Japanese Journal of Infection Diseases. 2010. Vol. 70, No. 1. P. 45–49.
67. Vu T.T., Holmes E.C., Duong V. [et al.]. Emergence of the Asian 1 genotype of dengue virus serotype 2 in Vietnam: in vivo fitness advantage and lineage replacement in South-East Asia // PLoS Negl. Trop. Dis. 2010. Vol. 4, No. 7. P. 1–11.
68. Wang Z., Liu T., Chen X. [et al.]. Low molecular weight fucoidan ameliorates hind limb ischemic injury in type 2 diabetic rats // J. Ethnopharmacol. 2018. Vol. 210. P. 434–442.
69. Wilder-Smith A., Leong W.Y. Importation of yellow fever into China: Assessing travel patterns // J. Travel Med. 2017. Vol. 24, No. 4. P. 1–4.
70. Wu J.Y., Lun Z. R., James A.A., Chen X.G. Review: dengue fever in mainland China // Am. J. Trop. Med. Hyg. 2010. Vol. 83, No. 3. P. 664–671.
71. Xu Y., Xu J., Ge K. [et al.]. Anti-inflammatory effect of low molecular weight fucoidan from Saccharina japonica on atherosclerosis in apoE-knockout mice // Int. J. Biol. Macromol. 2018. Vol. 118, Pt. A. P. 365–374.
72. Yoo S.J., Heo S.T., Lee K.H. Severe fever with thrombocytopenia syndrome // Korean J. Crit. Care Med. 2014. Vol. 29, No. 2. P. 59–63.
73. Yue Y., Ren, D., Liu Q. Spatial-temporal distribution of dengue fever in the mainland of China, 2005–2013 [in Chinese] // Disease Surveillance. 2015. Vol. 30. P. 555–560.
74. Zapata J.S., Cox D., Salvato M.S. The role of platelets in the pathogenesis of viral hemorrhagic fevers // PLoS Negl. Trop. Dis. 2014. Vol. 8, No. 6. P. 1–12.
75. Zhang S., Wang S., Yin W. [et al.]. Epidemic characteristics of hemorrhagic fever with renal syndrome in China, 2006–2012 // BMC Infect. Dis. 2014. Vol. 14, No. 384. P. 1–10.
76. Zhan J., Wang Q., Cheng J. [et al.]. Current status of severe fever with thrombocytopenia syndrome in China // Virologica Sinica. 2017. Vol. 32, No. 1. P. 51–62.
Review
For citations:
Kompanets G.G., Iunikhina O.V., Pott A.B., Krylova N.V. VIRAL HEMORRHAGIC FEVERS IN THE ASIAN PART OF ASIAN-PACIFIC REGION: EPIDEMIOLOGY, POTENTIALS FOR SPECIFIC TREATMENT, AND PREVENTION. Pacific Medical Journal. 2019;(3):11-18. (In Russ.) https://doi.org/10.17238/PmJ1609-1175.2019.3.11-18
Views:
730
Email this article 